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Relationship between age and MTX sensitivity as determined by the in situ thymidylate synthase inhibition assay (TSIA) Age:
Ͻ1 year у1 year P-value TSI 50 (n) TSI 50 (n) All Median TSI 50 values (m) represent the concentration of MTX necessary to inhibit 50% of the control TS activity. For the short exposure, cells were exposed to MTX for 3 h followed by an 18-h drug-free period. The continuous exposure was for 21 h. n = number of patient samples. P-values determined by the MannWhitney U test.
MLL rearrangements, respectively. No differences were observed between infants and patients у1 year within these categories (Table 1) . However, the number of samples with proB-ALL and/or MLL rearrangements у1 year of age is very small (n = 3 and 5, respectively); these results must therefore be regarded as descriptive. So far, no differences were seen between MLL rearranged (n = 34) and germline (n = 6) cases with the TSIA. It has been suggested that infants with the translocation t(4;11)(q21;q23) (MLL-AF4) might have a particularly poor prognosis. 7 We did not observe any difference in MTX resistance between MLL-AF4 positive (n = 16) and other MLL translocated infants (n = 9) with the TS inhibition assay (short and continuous exposure conditions). This small number of patients precludes definite conclusions. Further analysis of MTX-PG accumulation vs age within the proB immunophenotype and MLL gene rearranged groups was not possible.
For the in vivo MTX-PG part of this study, samples were analyzed from children treated with MTX as a single drug in an unfront window setting at St Jude Children's Research Hospital. 3 Five infants Ͻ1 year were compared with 159 children у1 year of age, diagnosed with non-hyperdiploid B-lineage ALL. Informed consent was obtained from each patient or his/her parents or guardian, as appropriate. At initial diagnosis, patients were randomized to receive either fractionated low-dose (LDMTX; 180 mg/m 2 , consisting of 30 mg/m 2 per os given every 6 h) or high-dose methotrexate monotherapy (HDMTX; 1000 mg/m 2 in a 24 h intravenous (i.v.) infusion). Bone marrow samples were obtained at 44 h after the start of LDMTX or HDMTX. The leukemic blast cells were isolated and MTX (ie MTX-Glu 1 ) and its polyglutamates (MTX-Glu 2-7 ) were analyzed by HPLC and radioligand binding-assay. 3 The infants had similar accumulation of total and long-chain MTX-PG in their leukemia cells, compared to older children with non-hyperdiploid B-lineage ALL. Moreover, HDMTX achieved higher MTX-PG in leukemia cells than lower-dose MTX among infants (median = 2560 with HDMTX vs 462 pmol/10 9 cells with LDMTX) and among older children (1501 vs 604 pmol/10 9 cells). In vivo pharmacokinetic data of MTX in infants are limited. MTX is eliminated by the kidneys, and hence might be expected to have
Figure 1
Relationship between age and in vitro MTX sensitivity in childhood B-lineage ALL. Determined by the in situ TS inhibition assay with continuous (a) and short (b) exposure to MTX, and by in vitro total MTX (c) and long-chain (4-6 glutamate residues; d) MTX polyglutamylate accumulation, for infants (Ͻ1 year) vs older (у1 year) childhood patients. The horizontal lines show the median values, the circles represent the individual patient samples. P-values determined by the Mann-Whitney U test. slower clearance in young infants. Data on the elimination of MTX in infants are somewhat conflicting, and not available in infants under the age of 2-3 months; however it seems that high doses of MTX are adequately tolerated. 8 Our data indicating that 1 g/m 2 i.v. achieved substantially higher MTX-PGs in infants than LDMTX suggest that higher doses of MTX are warranted in infants. Whether they should receive, or can tolerate, doses у1 g/m 2 remains to be shown. Moreover, intensive systemic and intrathecal chemotherapy regimens including HDMTX appear to be as effective as cranial irradiation in the treatment and prevention of central nervous system leukemia in infants with ALL. 7 The data from the present study suggest that infant (Ͻ1 year) ALL cells are not resistant to MTX, and have a sensitivity comparable to c/preB ALL у1 year of age, measured by the indirect in situ TS inhibition assay and by in vitro and in vivo MTX and MTX polyglutamate accumulation. This might also partly explain why recent protocols, that have included the addition of high-dose MTX, appear to improve the outcome of infants with ALL. 5 Hence, ALL in infants appears to be relatively sensitive to MTX; resistance to MTX most likely does not contribute to the poor prognosis of infant ALL. Taken together with reports that MTX-treatment is relatively well tolerated by infants, it is important to include MTX in infant ALL treatment schemes at adequately tolerated doses for both systemic and intrathecal treatment. 1 A previous report, analyzing patients with Ph-negative CML showed M-BCR rearrangement in 11 out of 23 patients.
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2 Insertion of a small segment of chromosome 9 (9q34) into chromosome 22q11 was suggested to form M-BCR in Ph-negative CML.
3,4 A unique complex translocation: t(9;12;15)(q34;q12;q21) in a CML patient has been reported to mask the Ph chromosome. 5 Fluorescence in situ hybridization (FISH) has become useful to confirm cytogenetic diagnosis in Ph-positive and -negative CML. 6 Seong et al, 7 using hypermetaphase FISH, reported that two out of six Ph-negative CML patients had ABL insertions into the BCR gene on chromosome 22. In Ph-negative CML, retranslocation between chromosomes 9q+ and 22q− was postulated to result in normal-looking chromosomes 9 and 22. 1 We here report a patient with t(20;22)(q13;q11) accompanying BCR-ABL fusion on chromosome 22 which resulted in a normal-looking cytogenetic study by the Giemsa-banding method.
A 61-year-old Japanese woman was found to have leukocytosis and thrombocytosis in September 2000. Physical examination showed no hepatosplenomegaly or any other abnormal findings. Laboratory data revealed a white blood cell (WBC) count of 19.2 × 10 /l) and myeloid hyperplasia (myeloyd/erythroid ratio, 12.9) with 2.4% myeloblasts, 1.2% promyelocytes, 13.2% eosinophils, 1.6% basophils and 6.4% erythroblasts. All of the hematologic results were compatible with typical CML. Chromosomal findings of bone marrow cells seemed to be 46,XX in 20 cells (Figure 1a ). Based on these data, Ph-negative CML was diagnosed. Detection of the major BCR-ABL mRNA of bone marrow cells from this patient by RT-PCR analysis was performed as previously described, 8 using a primer ABL1 (5′-GGC CCA TGG TAC CAG GAG TG-3′) as a reverse transcription primer, followed by the amplification of cDNA with a first primer pair ABL1 and BCR1 (5′-GCT TCT CCC TGA CAT CCG TG-3′) for 35 cycles and a second primer pair ABL2 (5′-GTT TCT CCA GAC TGT TGA CTG-3′) and BCR2 (5′-GGA GCT GCA GAT GCT GAC CAA C-3′) for 35 cycles, respectively. RT-PCR analysis detected a 446 bp major BCR-ABL transcript, corresponding to b3a2 fusion (Figure 1c) . FISH analysis of BCR-ABL fusion revealed 60.8% positive as compared to 1.9% positive in a normal control. Dual-color FISH analysis demonstrated a BCR-ABL fusion signal on one chromosome 22, a normal green ABL signal and a normal red BCR signal on one chromosome 9 and the other chromosome 22, respectively (Figure 1d ). Karyotyping by SKY 9 showed t(20;22) without detectable segmental translocation of the 9q34 region (Figure 1b) . She was given hydroxyurea for about 2 months, and then was given interferon-alpha after being found positive for major BCR-ABL by RT-PCR analysis.
Ph-negative and BCR-positive CML patients are now easily analyzed using molecular techniques. The finding of BCR-ABL molecular rearrangements indicates undetected Ph translocation in Ph-negative patients. Cytogenetic study in this patient failed to demonstrate Ph translocation. RT-PCR analysis indicated that this patient had BCR-ABL rearrangement. This finding was confirmed by dual-color FISH analysis demonstrating a BCR-ABL fusion signal on one chromosome 22. Meanwhile, karyotyping by SKY analysis demonstrated t(20;22) without abnormality in chromosome 9. These results indicate that only a small segment of chromosome 9 including ABL is located on chromosome 22. Inazawa et al 1 speculated that retranslocation between chromosome 9 and 22 might result in Ph-negative CML. Other reports suggested insertion of a small segment of chromosome 9 into chromosome 22 to form M-BCR in Ph-negative CML.
3,4 Moreover, masked Ph chromosomes in the literature usually have a 9q+ anomaly that inspires further examination of the translocated part on 9q34. However, the current case showed neither 9q+ nor 22q− anomaly using standard G-and Q-bandings.
A single cytogenetic event seems to be more plausible than a two-
